Testes-specific protease 50 as an independent risk factor for poor prognosis in patients with non-small cell lung cancer

• Published in: Oncology letters Vol. 15; no. 6; pp. 8796 - 8804
• Main Authors: Qiao, Wen-Liang, Shi, Bo-Wen, Han, Yu-Dong, Tang, Hua-Mei, Lin, Jun, Hu, Hai-Yang, Lin, Qiang
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.06.2018; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Binding sites; Breast cancer; Cancer therapies; Care and treatment; Chemotherapy; Confidence intervals; Development and progression; Gene expression; Genetic aspects; Health aspects; Lung cancer; Lymphatic system; Medical prognosis; Metastasis; Mortality; Multivariate analysis; Non-small cell lung cancer; Oncology; Proteases; Radiation therapy; Studies; Tumors; China; non-small cell lung cancer; survival analysis; cancer/testis antigens; prognosis; testes-specific protease 50
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2018.8387

Testes-specific protease 50 (TSP50) is normally expressed in the testes and is overexpressed in various types of human cancers, including breast cancer, colorectal carcinoma and laryngocarcinoma. However, little has been reported on the association between TSP50 and non-small cell lung cancer (NSCLC). The present study aimed to detect TSP50 expression in 198 strict follow-up cases of paired NSCLC and 15 cases of normal lung parenchymal specimens using immunohistochemical staining. The expression levels of TSP50 were then correlated with the clinicopathological factors of NSCLC to assess its potential diagnostic and prognostic value. The relationship between TSP50 expression and the clinicopathological parameters of NSCLC was evaluated using χ and Fisher's exact tests. Survival rates for the overall population (n=198) were calculated using the Kaplan-Meier method, and univariate and multivariate analyses were performed using the Cox's proportional hazards regression model. P<0.05 was considered to indicate a statistically significant difference. The expression of TSP50 was significantly increased in NSCLC tissue compared with in adjacent non-tumor or normal lung parenchymal tissue (P<0.001). A significant association was revealed between high expression levels of TSP50 and clinicopathological characteristics including tumor differentiation (P=0.012), late tumor status (P=0.004) and late tumor node metastasis stage (P=0.026), as well as a reduced disease free survival (P=0.009) and overall survival rate (P=0.002) in all patients with NSCLC. Multivariate analyses demonstrated that high TSP50 expression in tumor tissues was significantly associated with a shorter disease-free survival rate [hazard ratio (HR) =1.590, 95% confidence interval (CI): 1.035-2.441], and with a shorter overall survival rate (HR=1.814; 95% CI: 1.156-2.846). In conclusion, the present data demonstrated that increased TSP50 protein expression may be a potential predictor of early recurrence and poor prognosis in NSCLC, and that TSP50 expression levels possess the potential to be used as a biomarker and therapeutic target for the treatment of patients with NSCLC.